As China has entered a promising and brand new stage of new drug development in recent years, the continuous development and globalization of biotechnology and pharmaceutical innovation has placed higher demands on data innovation. As a technology-enabled full service CRO, it has been a key concern of Elixir Clinical Research to actively explore how to use big data to speed up drug development process.

Dedicated to quantitative science and empowering pharmaceutical innovation. From September 17-19, DIA together with International Chinese Statistical Association (ICSA), held the “2022 China Drug Research and Development Quantitative Science Forum (QSF)” in Nanjing. Experts, scholars, and young workers from companies, academia, and regulatory authorities were invited to share and exchange extensive information on relevant hot topics at home and abroad, and further explain how quantitative science can play a greater role in drug R&D. Elixir Clinical Research was invited to join the meeting.

Elixir Clinical Research showcased its high quality and efficacy clinical research solutions. By giving full play to its strengths in data, professional industrial experience and cutting-edge technology, it provides professionals in the drug development industry with diverse solutions throughout the entire process to help new drugs gain marketing authorization quickly.

Dr. Jie Chen, Chief Scientific Officer of Elixir Clinical Research, expressed his good wishes for QSF online as the co-chair of the 3rd QSF Organizing Committee, “My connection with QSF started in September 2010, and this year is its 10th anniversary. I wish QSF success and prosperity.”

Talent comes first before strategy implementation. Elixir Clinical Research firmly believes that data science talents are one of the keys to drug development and innovation in China. On September 19, the “First DIA Data Science National Competition” sponsored by Elixir Clinical Research was successfully held. Dr. Jie Chen, as one of the judges, witnessed many“rising stars” in the data science field.

The DIA Data Science National Competition is a national competition in the drug research and development industry, aiming to encourage college students and postgraduate students to engage in innovative practical activities in the drug innovation and health fields, and to provide them a competition platform to apply innovations. Together with DIA and other partners, Elixir Clinical Research has selected a group of top scientific reserve talents to serve drug development and guard patients’ needs, ultimately promoting internationalization for China’s pharmaceutical and health industry.

The new era of drug research and development is coming. Elixir Clinical Research is committed to providing pharmaceutical companies data solutions throughout the whole process with real and reliable data, combined with artificial intelligence technology, to help drug R&D continue to innovate and to accelerate drug marketing.